BLUE bluebird bio Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BLUE

Price (delayed)

$0.9125

Market cap

$99.77M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.6

Enterprise value

$238.13M

bluebird bio, Inc., based in Cambridge, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders and cancer. The company's only - in the European Union - ...

Highlights
The revenue has surged by 131% since the previous quarter
The gross margin has soared by 94% YoY and by 73% from the previous quarter
bluebird bio's equity has increased by 40% YoY but it has decreased by 23% from the previous quarter
The quick ratio has contracted by 36% from the previous quarter but it has grown by 3.3% YoY
bluebird bio's debt has increased by 9% YoY
Sector: Healthcare
Industry: Biotechnology
Peers: BMRN SGMO GLYC MRK

Key stats

What are the main financial stats of BLUE
Market
Shares outstanding
109.34M
Market cap
$99.77M
Enterprise value
$238.13M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.44
Price to sales (P/S)
4.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.96
Earnings
Revenue
$21.73M
EBIT
-$99.46M
EBITDA
-$95.08M
Free cash flow
-$85.64M
Per share
EPS
-$0.6
Free cash flow per share
-$0.78
Book value per share
$2.08
Revenue per share
$0.2
TBVPS
$5.52
Balance sheet
Total assets
$613.61M
Total liabilities
$391.07M
Debt
$303.71M
Equity
$222.54M
Working capital
$88.12M
Liquidity
Debt to equity
1.36
Current ratio
1.55
Quick ratio
1.24
Net debt/EBITDA
-1.46
Margins
EBITDA margin
-437.7%
Gross margin
-10.1%
Net margin
-419.6%
Operating margin
-626.7%
Efficiency
Return on assets
-14.4%
Return on equity
-34.3%
Return on invested capital
-16.5%
Return on capital employed
-21.9%
Return on sales
-457.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BLUE stock price

How has the bluebird bio stock price performed over time
Intraday
-0.82%
1 week
-3.95%
1 month
-32.9%
1 year
-75.14%
YTD
-33.88%
QTD
-28.71%

Financial performance

How have bluebird bio's revenue and profit performed over time
Revenue
$21.73M
Gross profit
-$2.19M
Operating income
-$136.15M
Net income
-$91.17M
Gross margin
-10.1%
Net margin
-419.6%
The revenue has surged by 131% since the previous quarter
bluebird bio's net margin has soared by 95% YoY and by 59% from the previous quarter
The gross margin has soared by 94% YoY and by 73% from the previous quarter
BLUE's operating margin has surged by 93% year-on-year and by 57% since the previous quarter

Growth

What is bluebird bio's growth rate over time

Valuation

What is bluebird bio stock price valuation
P/E
N/A
P/B
0.44
P/S
4.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.96
The EPS has surged by 90% year-on-year and by 32% since the previous quarter
BLUE's P/B is 80% below its 5-year quarterly average of 2.2 and 73% below its last 4 quarters average of 1.6
bluebird bio's equity has increased by 40% YoY but it has decreased by 23% from the previous quarter
The revenue has surged by 131% since the previous quarter
BLUE's P/S is 94% below its last 4 quarters average of 71.4

Efficiency

How efficient is bluebird bio business performance
The return on sales has surged by 95% year-on-year and by 58% since the previous quarter
bluebird bio's ROA has soared by 83% YoY and by 9% from the previous quarter
bluebird bio's return on invested capital has surged by 82% YoY
bluebird bio's ROE has soared by 82% YoY and by 11% from the previous quarter

Dividends

What is BLUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BLUE.

Financial health

How did bluebird bio financials performed over time
The total assets is 57% greater than the total liabilities
The quick ratio has contracted by 36% from the previous quarter but it has grown by 3.3% YoY
The current ratio has contracted by 27% from the previous quarter but it has grown by 22% YoY
bluebird bio's debt is 36% more than its equity
bluebird bio's equity has increased by 40% YoY but it has decreased by 23% from the previous quarter
BLUE's debt to equity is up by 28% since the previous quarter but it is down by 22% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.